Zobrazeno 1 - 10
of 94
pro vyhledávání: ''
Autor:
Teruhisa Tokunaga, Haruyuki Hongo, Kyoko Nakamura, Takako Nagao, Ichiro Koga, Tomomi Kitaichi, Akiko Fukuda, Yuko Maeno
Publikováno v:
Advances in Therapy
Introduction Dolutegravir (DTG), a novel HIV-integrase strand transfer inhibitor (INSTI), is usually used with multiple antiretrovirals (ARVs) for treatment of HIV. DTG is now approved as Tivicay tablets in over 120 countries and Triumeq combination
Publikováno v:
Advances in Therapy
Schizophrenia is characterized by positive, negative, cognitive, and affective symptoms. Antipsychotic medications, which work by blocking the dopamine D2 receptor, are the foundation of pharmacotherapy for schizophrenia to control positive symptoms.
Publikováno v:
Advances in Therapy. 38:2840-2853
Dipeptidyl peptidase 4 (DPP4) inhibitors and sodium-glucose co-transporter 2 (SGLT2) inhibitors have often been used for patients with T2DM because of the reduced risk of hypoglycemia. However, DPP4 inhibitors and SGLT2 inhibitors may increase the ri
Publikováno v:
Advances in Therapy. 38:1650-1659
Recently the phase 3 BEACON trial showed that the combination of encorafenib, cetuximab, and binimetinib versus cetuximab and irinotecan/FOLFIRI improved overall survival in pre-treated patients with metastatic colorectal cancer (mCRC) with BRAF V600
Autor:
Charmi Patel, Brahim Bookhart, Yen-Wen Chen, Christopher D Pericone, Bingcao Wu, Lawrence Blonde
Publikováno v:
Advances in Therapy. 38:594-606
While several sodium glucose co-transporter 2 (SGLT2) inhibitors are approved as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus (T2DM), there are no clinical trial data providing head-to-head com
Publikováno v:
Advances in Therapy. 38:399-412
The prospect of targeted therapies for advanced gastrointestinal stromal tumors (GISTs) has been dramatically transformed after encouraging results achieved in recent clinical trials. At present, the number of second- and third-line treatments are in
Autor:
Stephen K. Tyring, Javier Alonso-Llamazares, Jean-Philippe Lacour, Leon H Kircik, Mark Lebwohl, Richard B. Warren, Paul S. Yamauchi, Linda Stein Gold
Publikováno v:
Advances in Therapy
Background Psoriasis vulgaris is commonly treated with topical corticosteroids and vitamin D analogues. Although potent and super-potent topical corticosteroids are very effective at clearing psoriasis, with short-term reactive treatment durations, s
Publikováno v:
Advances in Therapy. 37:4233-4248
Although various therapies are available for the treatment of metastatic colorectal cancer (mCRC), there is lack of head-to-head evidence. Recent studies have demonstrated the efficacy of chemotherapy in combination with different biological agents i
Autor:
Fernando J. Martinez, Peter Lange, Maggie Tabberer, MeiLan K. Han, David M.G. Halpin, Morrys C. Kaisermann, Robert A. Wise, Dave Singh, Gerard J. Criner, David A. Lipson, David A. Lomas, Mark T. Dransfield, Sally Kilbride, C. Elaine Jones, Steven Pascoe
Publikováno v:
Adv Ther
Advances in Therapy
Tabberer, M, Jones, C E, Kilbride, S, Halpin, D M G, Lomas, D A, Pascoe, S, Singh, D, Wise, R A, Criner, G J, Lange, P, Dransfield, M T, Han, M K, Martinez, F J, Kaisermann, M C & Lipson, D A 2020, ' Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD : The IMPACT Study ', Advances in Therapy, vol. 37, no. 9, pp. 3775-3790 . https://doi.org/10.1007/s12325-020-01409-8
Advances in Therapy
Tabberer, M, Jones, C E, Kilbride, S, Halpin, D M G, Lomas, D A, Pascoe, S, Singh, D, Wise, R A, Criner, G J, Lange, P, Dransfield, M T, Han, M K, Martinez, F J, Kaisermann, M C & Lipson, D A 2020, ' Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD : The IMPACT Study ', Advances in Therapy, vol. 37, no. 9, pp. 3775-3790 . https://doi.org/10.1007/s12325-020-01409-8
Introduction The phase 3 InforMing the PAthway of COPD (chronic obstructive pulmonary disease) Treatment (IMPACT) trial, single-inhaler therapy with fluticasone furoate (FF) 100 μg, umeclidinium (UMEC) 62.5 μg, and vilanterol (VI) 25 μg demonstrat
Autor:
Li Liu, Daniel H. Leung, Betty B. Yao, Philip J. Rosenthal, Steven Lobritto, Evelyn K. Hsu, Michael R. Narkewicz, Christopher D. Jolley, Jean P. Molleston, Jiuhong Zha, Maureen M. Jonas, Jessica Wen
Publikováno v:
Advances in Therapy
Introduction To assess the safety, efficacy, and pharmacokinetics of mini-tablet formulations of ombitasvir (OBV), paritaprevir (PTV), ritonavir, and dasabuvir (DSV) with or without ribavirin for 12 weeks in children infected with chronic hepatitis C